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Abstract: Background: Influenza virus infection predisposes to secondary bacterial pneumonia.
Currently licensed influenza vaccines aim at the induction of neutralizing antibodies and are less
effective if the induction of neutralizing antibodies is low and/or the influenza virus changes
its antigenic surface. We investigated the effect of suboptimal vaccination on the outcome of
post-influenza bacterial superinfection. Methods: We established a mouse vaccination model
that allows control of disease severity after influenza virus infection despite inefficient induction
of virus-neutralizing antibody titers by vaccination. We investigated the effect of vaccination on
virus-induced host immune responses and on the outcome of superinfection with Staphylococcus aureus.
Results: Vaccination with trivalent inactivated virus vaccine (TIV) reduced morbidity after influenza
A virus infection but did not prevent virus replication completely. Despite the poor induction of
influenza-specific antibodies, TIV protected from mortality after bacterial superinfection. Vaccination
limited loss of alveolar macrophages and reduced levels of infiltrating pulmonary monocytes after
influenza virus infection. Interestingly, TIV vaccination resulted in enhanced levels of eosinophils
after influenza virus infection and recruitment of neutrophils in both lungs and mediastinal lymph
nodes after bacterial superinfection. Conclusion: These observations highlight the importance of
disease modulation by influenza vaccination, even when suboptimal, and suggest that influenza
vaccination is still beneficial to protect during bacterial superinfection in the absence of complete
virus neutralization.
Keywords: influenza; TIV; bacterial superinfection; Staphylococcus aureus; macrophage;
eosinophil; neutrophil
1. Introduction
Over the course of a lifetime, humans build up immunity to influenza viruses through natural
infection and vaccination. Currently licensed vaccines aim at the induction of virus neutralizing
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antibodies. The gold correlate of protection so far is an in vitro surrogate assay for virus neutralization
based on the ability of serum antibodies to prevent virus from agglutinating red blood cells, which is
called hemagglutination inhibition (HI). The presence of such antibodies is associated with a reduction
in the likelihood of morbidity upon exposure to influenza virus [1]. Protection provided by neutralizing
antibodies is, however, limited in time, since influenza virus can change its antigenic surface through
antigenic drift and shift, or because levels of neutralizing antibodies wane over time. There is an
abundance of literature that describes mechanisms other than virus-neutralizing antibodies that can
contribute to protection against influenza-associated morbidity and mortality [2–6]. In fact, it is very
likely that, in the absence of virus-neutralizing antibodies, influenza virus-induced disease is modulated
instead of prevented in the human host by non-neutralizing pre-existing immunity. As a result, host
immune responses to the virus are also skewed during infection by pre-existing immunity. This is
often not reflected in preclinical animal models for influenza virus infection since mostly naïve animals
are used. To better reflect the human situation, we developed a mouse model in which we induce
influenza-specific pre-existing immunity that allows virus replication but confers disease protection.
Infection-permissive pre-existing immunity is induced by intramuscular vaccination with trivalent
inactivated virus vaccine (TIV) adjuvanted with alhydrogel (alum). With this model, we study the initial
host immune response to infection with a sublethal dose of H1N1 influenza virus that is homologous
to the H1N1 component of the TIV. We show that TIV is disease protective, even in the absence of
detectable virus-neutralizing antibodies, and skews host immune responses upon infection. It has been
described that influenza virus infection can predispose the host for bacterial pneumonia [7–9], and
bacterial superinfection during influenza outbreaks is a major cause of influenza-related death [10].
Therefore, we also investigated the effect of pre-existing immunity provided by TIV on the outcome
of Staphylococcus aureus superinfection. Modulation of influenza-related disease by TIV was able to
prevent mortality during superinfection, and this was associated with enhanced neutrophil recruitment
to the lungs and mediastinal lymph nodes. Therefore, TIV vaccination was not only able to protect
from disease after initial influenza virus infection, but also indirectly during secondary bacterial
superinfection. The results described in this manuscript provide insights as to how influenza-specific
pre-existing immunity can ameliorate the host response to both influenza virus infection and bacterial
superinfection in the absence of detectable neutralizing antibodies.
2. Materials and Methods
2.1. Study Design
For this study, two experiments were carried out. The schematic outline for Experiment 1 and
Experiment 2 are shown in Figure 1. Briefly, for Experiment 1, fifty mice were either vaccinated with
TIV (n = 25) or administered with PBS (n = 25) on day 21. Both groups were then challenged with a
sublethal dose of NC99 H1N1 virus three weeks later (day 0). Body weights were monitored for up
to 14 days post infection. One week after virus infection (day 7), remaining mice in the two groups
were further divided in half to infect with S. aureus (SA) or a control treatment with PBS. Experiment
2 was set up in the same way as Experiment 1, but with addition of control mock infection with
allantoic fluid, which brought the total number of mice to 96. For serology, blood was collected 14 days
post vaccination (day 7) in both experiments. For lung viral titers, lungs were harvested at 3, 7 and
9 days post infection (dpi) for Experiment 1 and at 3 and 9 dpi for Experiment 2. In both experiments,
bacterial loads were measured from lungs harvested at 2 days post S. aureus infection (9 days post
H1N1 infection). To investigate host immune responses, flow cytometry was performed on samples
collected on different time points. In Experiment 1, lung samples were collected at 7 and 9 days post
H1N1 infection (day 7 and day 9). Additionally, at day 9, mediastinal lymph nodes were collected.
Flow cytometry analysis in Experiment 2 was performed only on lungs that were harvested at 8 days
post H1N1 infection (day 8).
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Figure 1. Outlines for Experiment 1 and 2. Mice were TIV vaccinated or control vaccinated with PBS 
21 days before infection with NC99 H1N1 virus. In Experiment 2, a mock challenged control group 
was also included. Blood for serology was collected 14 days after vaccination. Lungs were collected 
for virus titration at 3 dpi, 7 dpi (only Experiment 1) and 9 dpi. Bacterial superinfection was given at 
7 dpi and bacterial loads were determined at 9 dpi. Flow cytometry for investigating host immune 
responses was done on samples collected at 7 dpi (Experiment 1), 8 dpi (Experiment 2) and 9 dpi 
(Experiment 1). PBS: phosphate buffered saline, TIV: trivalent inactivated virus vaccine, SA: 
Staphylococcus aureus, PFU: virus plaque forming units, CFU: bacterial colony forming units. 
2.2. Mice, Vaccination and Serology 
Female Balb/c mice aged 6–8 weeks were obtained from Charles River Laboratories (Balb/c 
AnNCrl) and housed under specified pathogen-free conditions with food and water ad libitum. 
Trivalent inactivated virus vaccine (TIV) was the human Aventis-Pasteur vaccine (2005–2006 
formula) containing the antigens from the following influenza viruses: A/New Caledonia/20/99 
H1N1 virus, A/New York/55/2004 and B/Jiangsu/10/2003. Vaccine was obtained from BEI resource 
and mixed with alhydrogel (Alum, Invivogen, San Diego, CA, USA) before incubation at 4 °C 
according to the manufacturer’s directions. Vaccine was injected once via the intramuscular route 
with a BD 300 μL insulin syringe in the quadriceps muscles of the hind legs (100 μL divided over 
both legs). The administered vaccine dose corresponds to 3 μg of each hemagglutinin type in the 
vaccine per mouse. Control groups were injected with phosphate buffered saline (PBS) mixed with 
Alum. 
Blood was collected at the indicated time points via submandibular bleeding and serum was 
prepared by allowing the blood to clot at room temperature. Anti-HA antibody responses were 
measured by enhanced luminescent immunosorbent assay (ELISA) and hemagglutination inhibition 
(HI) assay. For quantification of HA-specific total IgG levels by ELISA, 96 well NUNC Maxisorp 
plates were coated with baculovirus-derived recombinant HA from A/New Caledonia/20/99 in 
bicarbonate buffer at 4 °C overnight. After washing and blocking with 4% milk for 1 h at room 
temperature, serum samples diluted 1/100 in PBS with 0.05% Tween20 are allowed to bind ELISA 
antigen for 1.5 h at room temperature. Plates were washed three times with PBS (0.05% Tween20) 
and incubated with sheep-derived anti-mouse IgG serum conjugated to horse-radish peroxidase (GE 
Healthcare, Amersham, UK). After a final washing step, tetramethylbenzidine substrate (Sigma-
Figure 1. Outlines for Experiment 1 and 2. Mice were TIV vaccinated or control vaccinated with PBS 21
days before infection with NC99 H1N1 virus. In Experiment 2, a mock challenged control group was
also included. Blood for serology was collected 14 days after vaccination. Lungs were collected for
virus titration at 3 dpi, 7 dpi (only Experiment 1) and 9 dpi. Bacterial superinfection was given at 7 dpi
and bacterial loads were determined at 9 dpi. Flow cytometry for investigating host immune responses
was done on samples collected at 7 dpi (Experiment 1), 8 dpi (Experiment 2) and 9 dpi (Experiment 1).
PBS: phosphate buffered saline, TIV: trivalent inactivated virus vaccine, SA: Staphylococcus aureus, PFU:
virus plaque forming units, CFU: bacterial colony forming units.
2.2. Mice, Vaccination and Serology
Female Balb/c mice aged 6–8 weeks were obtained from Charles River Laboratories (Balb/c
AnNCrl) and housed under specified pathogen-free conditions with food and water ad libitum.
Trivalent inactivated virus vaccine (TIV) was the human Aventis-Pasteur vaccine (2005–2006
formula) containing the antigens from the following influenza viruses: A/New Caledonia/20/99 H1N1
virus, A/New York/55/2004 and B/Jiangsu/10/2003. Vaccine was obtained from BEI resource and
mixed with alhydrogel (Alum, Invivogen, San Diego, CA, USA) before incubation at 4 ◦C according
to the manufacturer’s directions. Vaccine was injected once via the intramuscular route with a BD
300 µL insulin syringe in the quadriceps muscles of the hind legs (100 µL divided over both legs).
The administered vaccine dose corresponds to 3 µg of each hemagglutinin type in the vaccine per
mouse. Control groups were injected with phosphate buffered saline (PBS) mixed with Alum.
Blood was collected at the indicated time points via submandibular bleeding and serum was
prepared by allowing the blood to clot at room temperature. Anti-HA antibody responses were
measured by enhanced luminescent immunosorbent assay (ELISA) and hemagglutination inhibition
(HI) assay. For quantification of HA-specific total IgG levels by ELISA, 96 well NUNC Maxisorp plates
were coated with baculovirus-derived recombinant HA from A/New Caledonia/20/99 in bicarbonate
buffer at 4 ◦C overnight. After washing and blocking with 4% milk for 1 h at room temperature,
serum samples diluted 1/100 in PBS with 0.05% Tween20 are allowed to bind ELISA antigen for 1.5 h
at room temperature. Plates were washed three times with PBS (0.05% Tween20) and incubated
with sheep-derived anti-mouse IgG serum conjugated to horse-radish peroxidase (GE Healthcare,
Amersham, UK). After a final washing step, tetramethylbenzidine substrate (Sigma-Aldrich, San Diego,
CA, USA) was used to estimate levels of HA-specific mouse IgG by measuring the OD450 with the
OD650 as a reference.
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Hemagglutination inhibition was performed as previously described [5]. Briefly, four volumes of
receptor destroying enzyme (RDE, Vibrio cholera filtrate, Sigma Aldrich, San Diego, CA, USA) were
added to each volume of mouse serum. After overnight incubation at 37 ◦C, sera were heat-inactivated
at 56 ◦C for 30 min in citrate buffer. Four hemagglutination units of A/New Caledonia/20/99 were
mixed with twofold dilutions of treated sera in a final volume of 50 µL. Mixtures of virus and diluted
serum were allowed to bind for 1h at room temperature before 50 µL of 0.5% chicken red blood cell
suspension was added. HI titers were read after 1h incubation on ice.
2.3. Experimental Infection with Influenza Virus and Staphylococcus aureus
Three weeks after vaccination, mice were challenged intranasally with 50 µL of a sublethal dose of
egg-grown A/New Caledonia/20/99 H1N1 virus (400 plaque forming units, PFU) preparation diluted in
PBS under mild ketamine/xylazine anesthesia. Mock-challenged mice received diluted allantoic fluid
instead of virus. For bacterial superinfections, Staphylococcus aureus was grown in Bacto tryptic soy
broth (BD, Sparks, MD, USA) to an OD600 of 1.4. This guaranteed that bacterial growth was in the log
phase. 108 colony forming units (CFU) were administered intranasally at 7 days post influenza virus
infection in 50 µL under mild ketamine/xylazine anesthesia. Control mice received the same volume of
PBS instead of bacteria suspension. Body weight loss was measured on a daily base as a read-out for
morbidity. All experiments were approved by and performed according to the guidelines of the Icahn
School of Medicine at Mount Sinai Institutional Animal Care and Use Committee (IACUC-2017-0330).
The methods used were carried out in accordance with the approved guidelines. Mice were euthanized
when they had reached the ethical endpoint of 25% body weight loss.
2.4. Lung Virus Titers
Lung virus titers were quantified by plaque assays as described before [11]. Briefly, the mice were
sacrificed, and the lungs were removed aseptically at the indicated time points and homogenized in
PBS with a Benchmark Beadblaster 24 (Benchmark Scientific, Edison, NJ, USA). Lung homogenates
were cleared by centrifugation (16,000× g) at 4 ◦C and stored at −80 ◦C. For plaque assays, 250 µL of
tenfold dilutions in PBS of lung homogenate suspensions were incubated on confluent monolayers
of Madin Darbin Canine Kidney cells at 37 ◦C. After 1 h incubation, the inoculum was removed by
aspiration and cells were overlaid with 2% oxoid agar (Oxoid, Basingstoke, UK) mixed with an equal
volume of NaHCO3-buffered 2xMEM supplemented with DEAE/Dextran and TPCK-treated trypsin
(1 µg/mL). Cells were incubated for 48 h at 37 ◦C and 5% CO2. Plaque formation was visualized by
staining of cell surfaces after fixation with 4% formaldehyde (5 min at room temperature). For staining,
cells were incubated with a 1/1000 dilution of post challenge mouse serum followed by incubation
with 1/1000 diluted sheep anti-mouse serum conjugated to horse radish peroxidase (GE Healthcare)
and addition of TrueBlue substrate (KPL—Seracare, Milford, MA, USA).
2.5. Lung Bacterial Titers
Lungs were collected aseptically at the indicated time points and forced over a sterile 40 µm filter
(Sigma, St. Louis, MO, USA) with the back of a 1 mL syringe. Lung bacterial titers were quantified by
homogenizing lungs in PBS and plating different dilutions on tryptic soy agar bacterial plates. After
overnight incubation at 37 ◦C, colony forming units (CFU) were counted.
2.6. Flow Cytometry
2.6.1. Sample Preparation
Lungs and peribronchial lymph nodes were collected at the indicated time points. Lungs were
cut into cubes of one cubic mm and digested with Type IV Collagenase (Sigma, St. Louis, MO, USA) in
RPMI (Gibco, Grand Island, NY, USA) for 30 min at 37 ◦C. After incubation, single cell suspensions
were made by forcing lung tissue over a 40 µm filter (Sigma) with the back of a 1 mL syringe. In a
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similar way, lymph nodes were pooled and forced over a 40 µm filter (Sigma) with the back of a
1 mL syringe to obtain single cell suspensions. Cells were stained in 100 µL volume of FACS buffer
(PBS + 0.5% bovine serum albumin (BSA) and 2 mM EDTA (Sigma)) with a viability dye (eFluor 520
and eFluor 780, eBiosciences, San Diego, CA, USA) and antibodies (all from BD Pharmingen unless
mentioned otherwise) that target the following surface markers as mentioned in the text: CD11b
(clone M1/70, APC), CD11c (clone HL3, PE-Cy7), SiglecF (clone E50-2440, PE-CF594), MerTK (clone
DS5MMER, PE-Cy7 from eBioscience, CD64 (clone X54-5/7.1, PE), MHCII (clone M5/114.15.2, eFluor
450 from eBioscience), Ly6G (clone 1A8-Ly6g, eFluor 450 from eBioscience). Staining was done at room
temperature for 30 min in the dark. Cells were washed twice with FACS buffer before analysis on a
Beckman Coulter Gallios Flow cytometer. For estimation of absolute cell numbers, counting beads
(Thermofisher, Eugene, OR, USA) were added to the samples.
2.6.2. Analysis of Flow Cytometry Data
Flow cytometry data analysis was performed using FlowJo version X.0.7 (Treestar Inc., Ashland,
OR, USA) for classical hierarchical gating using two-dimensional plots. For unsupervised analysis
of samples collected at 8 days post infection in Experiment 2, compensated flow cytometry files
were loaded in FlowJo for preprocessing: Single live cells were gated and exported as new FCS 3.0
files. Exported flow cytometry data were then further analyzed using the R/Bioconductor packages
flowCore and matrixStats. Marker intensities were arcsinh-transformed (cofactor = 150) and scaled
between values 0 to 1 for visualization. Packages ConsensusClusterPlus and FlowSOM are used for
cell clustering and visualized using the packages Rtsne, ggplot2, pheatmap and RcolorBrewer.
2.7. Statistical Analysis
Statistical analyses were performed with Graphpad Prism version 7.00 for Windows (GraphPad
Software, San Diego, CA, USA) and with the R language and environment for statistical computing,
R Development Core Team, 2009 (R Foundation for Statistical Computing, Vienna, Austria
(ISBN 3-900051-07-0, URL http://www.R-project.org). The statistical tests used for computing
significance levels are mentioned in the text. Significance levels are mentioned in the text or indicated
with single asterisk (p < 0.05) or double asterisks (p < 0.01) in figures when not mentioned in the text.
3. Results
3.1. Single TIV Vaccination Does Not Result in Efficient Induction of Virus-Neutralizing HI Antibodies and
Is Infection-Permissive
Blood was collected two weeks after vaccination by submandibular bleeding. Single administration
of TIV with the equivalent of 3 mg hemagglutinin (HA) was able to induce NC99 H1-specific HA
ELISA titers in most samples tested (Figure 2A). When these serum samples were then tested for
their capacity to inhibit virus-mediated hemagglutination of red blood cells, a proxy assay for virus
neutralization, only 33% of the samples from TIV-vaccinated mice tested had an HI titer at or above
the detection limit (HI titer = 10) (Figure 2B).
The poor induction of detectable neutralizing antibodies by TIV vaccination was further reflected
by the presence of detectable lung virus titers in vaccinated mice at 3 days post infection (dpi) in both
experiments (Figure 3A,B). Vaccination, however, reduced lung virus titers about tenfold (Experiment
2) up to 100-fold (Experiment 1) compared to control vaccinated animals at 3 dpi and virus was
controlled in three out of four mice by 7 dpi (Figure 3A,B). No lung virus titers above detection limit
were observed by 9 dpi (Figure 3A,B). In conclusion, TIV vaccination did not result in sterilizing
immunity but aided virus clearance from the lungs of infected mice.
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Control-vaccinated mice lost 20% to 25% on average of their initial body weight after infection
with NC99 virus (Figures 4A and 5A). The challenge was sublethal for all mice in Experiment 1 but
was lethal to some mice in Experiment 2 (Figures 4B and 5C). Virus-induced morbidity was further
enhanced and resulted in mortality when mice were given a superinfection with 108 colony forming
units of S. aureus at 7dpi (Figure 4A,B and Figure 5A,C). Bacterial infection without previous influenza
infection resulted in 15% of body weight loss and mice starte to recover after 2 days (Figures 4A
and 5A). Vaccination induced control of morbidity after NC99 H1N1 influenza virus infection and
prevented mortality during bacterial superinfection (Figure 4A,B and Figure 5B,C). There seems to be
a trend of better control of bacterial load in vaccinated mice compared to control vaccinated mice 2
days after bacterial superinfection (Figure 6); however, there was too much variation in bacterial titers
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to draw solid conclusions on this point with the number of mice we sampled. A similar observation
was made by Chaussee et al. in a mouse model for post-influenza superinfection with Streptococcus
pyogenes and vaccination [8].
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3.3. TIV Vaccination Modulates the Host Immune Response to Both Influenza Virus Infection and
S. aureus Superinfection
The infection-permissive nature of TIV vaccination suggests that the host mounts a host immune
response to the infection. It has been described for the Balb/c mouse model that alveolar macrophages
are depleted after influenza virus infection [12–14]. This can predispose to severe disease during
bacterial superinfection. In Experiment 1, we therefore quantified the absolute number of alveolar
macrophages (alive CD45+ CD11c+ SiglecF+ CD11b- CD64+ MerTK+) in lung tissue at 7 dpi with
influenza virus. We observed that despite virus replication, alveolar macrophages are protected to
some extent during influenza virus infection in TIV vaccinated mice, but not in control vaccinated
mice (Figure 7A). Neutrophils are important for host defense during bacterial infections and their
function can be impaired by influenza infection [15]. Two days later, at 9 dpi with influenza virus,
which is 2 days after bacterial superinfection, we monitored neutrophil levels in both lung tissue and
lung-draining lymph nodes. Bacterial superinfection with S. aureus resulted in a modest increase of
neutrophils in control vaccinated animals, which was almost fourfold higher in vaccinated animals
(Figure 7B). The enhanced levels of neutrophils (alive Ly6G+ CD11b+) in lungs of TIV vaccinated
animals are also reflected in the lung-draining lymph nodes (Figure 7C).
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In Experiment 2, we further characterized the effect of TIV vaccination on virus-host immune
responses at 8 dpi with influenza virus (no samples from animals that received bacterial superinfection
were included). We decided to do an unsupervised approach to cluster cells with similar expression
levels of surface markers (CD45, CD11b, CD11c, CD64, SiglecF and MHCII) using the FlowSOM
algorithm [16] after “classical” hierarchical gating on single live CD45+ cells. This makes it possible
to visualize (the abundance of) multiple cell types present in different samples in one plot. Another
advantage is that no prior knowledge of the cellular composition of the samples is required. Although
already used for selecting immune cells before starting the unsupervised analysis, expression levels
of CD45 were also considered for clustering since expression levels can differ based on the type of
immune cell. With this antibody panel, we defined 10 clusters (Figure 8A). Using this approach,
we could clearly separate alveolar macrophages from other immune cells (Figure 8B) and observed
that alveolar macrophages are depleted at 8 days post infection in control vaccinated animals but not
in TIV vaccinated animals (Figure 8B,C). This confirmed our observations for 7 dpi in Experiment 1.
The advantage of using dimension reduction implementations like t-SNE is that different cell populations
can be visualized simultaneously without prior knowledge of the cell populations present in the
sample (Figure 8B). This allows a more complete overview of the dynamics of different immune cell
populations at a certain time point for the different conditions we tested. As such, we were able to
define a cell population that was enriched uniquely in TIV-vaccinated animals and that was almost
absent in control vaccinated animals after influenza virus infection. This cell population was also not
enriched in TIV or control vaccinated animals without influenza virus infection. The surface marker
expression profile identified this population as eosinophils (CD11b+ SiglecF+ CD11c-). On the other
hand, CD11b- DCs, characterized as CD11b- CD11c+ CD64-SiglecF- population with intermediate
MHCII levels, seemed to be enriched in control vaccinated animals after influenza virus infection.
The myeloid compartment in the influenza virus-infected lung is a complex mixture of immune cells
from different lineages and ontogeny [17,18]. Nevertheless, the limited number of markers used in this
analysis allows to illustrate the dynamics of other immune populations other than eosinophils and
alveolar macrophages after influenza virus infection and how they are skewed by TIV vaccination.
We named cells that expressed CD11b in combination with another monocyte-associated markers
“monocyte-like immune cells” (Figure 8). Some of these monocyte-like immune cells have intermediate
levels of CD11c and other markers typically associated with DCs and/or alveolar macrophages like
MHCII, CD11b, SiglecF or CD64 (Figure 8A). This suggests that some of the monocyte-like immune
cell populations observed in Figure 8B represent lung-infiltrating monocytes that transition into
DCs or alveolar macrophages. Compared to mock infected animals, proportions of the different
“monocyte-like immune cell” populations changed after infection in TIV vaccinated animals, which
was more pronounced in control vaccinated animals after infection, reflecting the higher morbidity
that the latter group experienced after infection (Figure 8B,C).
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Every plot represents subsamples of 3000 cells/mouse with n = 3 mice/group. (C) Proportions of the
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4. Discussion
Split vaccines are widely used to try to prevent influenza virus-related morbidity and mortality in
the human population. Induction of virus-neutralizing antibodies against circulating virus strains
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correlates with protection. However, even if vaccine strains and circulating viruses match antigenically,
levels of neutralizing antibodies in vaccinees can be too low to be measured by in vitro assays like
the hemagglutination inhibition assay or microneutralization assays. The reasons for low antibody
titers can be multiple, ranging from poor induction of initial antibody responses to waning antibody
levels over time, even after successful vaccination. In the absence of sufficient neutralizing antibodies,
virus replication cannot be prevented, and the host can still induce immune responses to the infection.
In this work, we showed that protection from disease provided by influenza vaccination with a human
TIV does not necessarily correlate with induction of neutralizing antibodies in sera as measured by
inhibition of hemagglutination of red blood cells. Therefore, assays other than hemagglutination
inhibition are needed to fully assess the protective effect of TIV vaccination, as well as to understand
the contribution of pre-existing immunity. In the absence of detectable hemagglutination inhibitory
(HI) antibody titers in sera, TIV-mediated protection was infection-permissive, meaning that virus
replication was allowed to some extent. We also showed that pre-existing immunity provided by TIV
vaccination in the absence of detectable HI titers in sera skews host responses to virus infection. In Balb/c
mice, experimental infection with influenza virus results in death of alveolar macrophages [12–14].
TIV vaccination prevented complete loss of alveolar macrophages, despite the presence of replicating
virus. This may suggest that in TIV vaccinated mice virus replication is more restricted, allowing
macrophages to survive where virus is not replicating or replicating at lower titers.
Severe influenza pathogenesis can be the result of pneumonia caused by superinfection with
bacterial pathogens like Streptococcus pneumoniae and Staphylococcus aureus [10]. In fact, re-analysis
of efficacy studies of bacterial vaccines used during the 1918 influenza pandemic showed that
vaccine-induced antibacterial immunity correlated with protection from pneumonia and death [19].
Preventing pathogenesis during influenza infection by vaccination also protects from bacterial
superinfection [8,20,21] and antibacterial vaccination can protect during post-influenza bacterial
superinfection [22]. However, influenza infection can also make antibacterial vaccination less effective
in the context of bacterial superinfection [23]. From preclinical animal models it is known that
predisposition of influenza virus-infected hosts to bacterial superinfection is linked to alveolar
macrophage death as well as to alveolar macrophages and other phagocytes becoming unresponsive
to innate stimuli by exposure to interferon induced by the prior virus infection [7,12,20,24]. Contrary
to PBS vaccinated animals, virus replication in TIV vaccinated mice did not result in detectable levels
of type I interferons and reduces induction of antiviral IFNγ-producing T cell responses (Choi et al.,
manuscript in preparation), and therefore alveolar macrophages may not be exposed to interferon to the
same extent. In our model, Staphylococcus aureus infection alone was not lethal, whereas superinfection
after prior influenza infection was lethal in mice that received PBS, but not in TIV-vaccinated animals.
In line with the enhanced morbidity observed after influenza virus infection in PBS-vaccinated mice
compared to TIV mice, we observed more infiltration of monocyte-like immune cells in the lungs of
PBS mice at 7 dpi. It has recently been described that a high ratio of lung-infiltrating monocytes over
tissue-resident alveolar macrophages correlates with high pathogenicity in mice during influenza virus
infection [25] and expression of CCR2, a marker associated with monocyte lineages, correlates with
increased susceptibility to post-H1N1 Staphylococcus aureus superinfection by affecting dendritic cell
functionality [26].
Interestingly, TIV vaccination resulted in enhanced infiltration of neutrophils in influenza virus
infected lungs. Higher levels of neutrophils contribute to protection during bacterial pneumonia
by phagocytosis and induction of anti-bacterial responses [27]. Neutrophil recruitment during
post-H1N1 bacterial superinfection with S. pneumoniae and S. aureus relies on the production of IL17
and neutrophil attractants CXCL1 and CXCL2, and both are negatively affected by virus-induced type
I interferon [28–31]. Reduction of virus replication and IFN production by vaccination can explain why
TIV mice have more neutrophil influx upon bacterial superinfection. The importance of neutrophil
infiltration in mediastinal lymph nodes for protection is unclear but they may shape humoral immune
responses through interaction with B cells [32].
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The recruitment of eosinophils into the lungs after respiratory infection of immunized hosts is
dogmatically associated with negative outcome of disease, e.g., during infections with respiratory
syncytial virus [33]. However, eosinophils have the molecular arsenal to fight bacterial infections [34]
and have recently been shown to correlate with protection during influenza virus infections by both
direct antiviral effects [35] and antigen-presentation to T cells [36]. Ongoing research in our laboratory is
looking into a potential role for alveolar macrophages in recruiting eosinophils and neutrophils during
infection in alum-adjuvanted, TIV-vaccinated mice, for example through the secretion of chemokines
like eotaxin.
A limitation of this study is that we performed influenza challenge experiments only with H1N1
NC99 virus. The other two types of influenza viruses that are responsible for morbidity and mortality
in the human population are H3N2 and influenza B viruses. We did not test those virus strains in our
model at this point, because we did not have mouse-adapted H3N2 and influenza B virus available
that matches the strains contained in the TIV we used.
In this study, we combined the influenza mouse model for post-influenza bacterial superinfection
with one for TIV vaccination to show that even without efficient induction of HI titers, TIV vaccination
protected against lethal bacterial superinfection. TIV vaccination resulted in disease modulation with
skewing of host responses to both influenza virus infection and bacterial superinfection. This highlights
that other vaccine correlates of protection against influenza are needed beyond HI titers to effectively
assess the protective effect of vaccination. In the mouse model we used infection with H1N1 NC99
already resulted in severe morbidity, which in combination with bacterial superinfection resulted in
mortality. Therefore, we could not study the effect of bacterial superinfection on the host immune
response to influenza virus infection in unvaccinated convalescent mice. To study this, we would
need to repeat the experiments with lower doses of challenge virus. These observations also highlight
the importance of disease modulation by influenza vaccination in the absence of virus neutralization
and suggest that vaccination is still beneficial to prevent (severe complications during) bacterial
superinfection even in the absence of virus neutralization. This understanding is important since
avoiding bacterial pneumonia by influenza vaccination reduces antibiotics prescriptions [37], which is
why influenza vaccination needs to be considered as a public health measure for the battle against
antimicrobial resistance [38]. The findings of this study support the encouragement of influenza
vaccination for target groups that are at higher risk for complications during influenza infection, like
the elderly, who are at risk for developing influenza-associated complications such as post-influenza
bacterial superinfections.
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